Sharemaestro Newsreel

IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss

Immunocore Holdings plc IMCR posted second-quarter 2026 revenues of $115.9 million, up 18.3% year over year and above the Zacks Consensus Estimate of $114 million. The company's loss of 2 cents per share, however, was wider than the consensus estimate of a loss of …

European Stocks Close Mixed in Monday Trading as Investors Monitor Middle East War Developments

The European stock markets closed mixed in Monday trading as investors continue to gauge development PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

How smart investors use ETFs to legally bypass IRS wash sale rules

Tax loss harvesting is a very effective strategy for investors to trim their tax bill each year. Selling underperforming holdings in a taxable account for a loss can help offset gains realized elsewhere. You can use losses to offset realized capital gains and can …

BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?

Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 16.2% over the past three months compared with the industry's growth of 6.8%. The stock has also outperformed both the sector and the S&P 500. …

Vertex Pharmaceuticals (VRTX) Is Up 5.4% After Raising 2026 Revenue Guidance And Expanding Its Pipeline - Has The Bull Case Changed?

Vertex Pharmaceuticals recently reported second-quarter 2026 results, with revenue rising to US$3,333.9 million and net income reaching US$1,099.8 million, and raised its full-year 2026 revenue guidance to US$13.10–US$13.20 billion. At the same time, a new collaboration with AbCellera on multispecific T‑cell engagers and a …

EDWARDS LIFESCIENCES AKTIE: AI-Analysen, Prognose & Kursziel

Should You Buy, Hold or Sell ABT Stock Amid Medical Devices Boom?

Abbott Laboratories' ABT Medical Devices remains its largest segment and continues to benefit from a strong pipeline of new product launches and growing adoption across cardiovascular care and diabetes management. The segment is well positioned to capitalize on the expanding global medical devices market. …

ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?

Intuitive Surgical ISRG currently trades at a forward 12-month P/E ratio of 33.02X, above the Medical - Instruments industry's 26.53X, underscoring a valuation premium that investors must weigh against the company's growth prospects. The stock carries a Value Score of D, suggesting that shares …

SANOFI AKTIE: AI-Analysen, Prognose & Kursziel

Major Depressive Disorder Market is Predicted to Grow During the Forecast Period (2026-2036) as Novel Antidepressants are Expected to Enter the Market | DelveInsight

The major depressive disorder market is experiencing a significant transformation as rapid-acting therapies with novel mechanisms of action complement conventional SSRIs and SNRIs. Recent treatment approvals have broadened therapeutic choices for patients with TRD and those who do not achieve adequate benefit from standard …

Aspo Plc - Managers' Transactions

Aspo Plc Aspo Plc Managers' transactions August 10, 2026 at 17.30 EET Aspo Plc - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: AEV Capital Holding Oy Position: Member of the Board/Deputy member (X) Legal person (1): Person Discharging Managerial Responsibilities In …

Bristol Myers To Invest $2.3 Bln In Houston Manufacturing Campus; To Create 500 Skilled Jobs

(RTTNews) - Bristol Myers Squibb (BMY) announced Monday an investment of approximately $2.3 billion in the U.S., while selecting Houston, Texas, as the site for a new, state-of-the-art multi-modal manufacturing campus to accelerate the delivery of next-generation medicines to patients. The approximately 600,000 square …

Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months

Shares of Replimune Group REPL have surged nearly 223% over the past three months, as the company steadily advanced its lead oncolytic immunotherapy, RP1 (vusolimogene oderparepvec), toward regulatory approval and strengthened the broader pipeline. The rally has been driven primarily by a series of …

This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.

New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading

Lifespan Vision Ventures Leads Remedium Bio's Series A Financing

Investment supports advancement of Remedium's durable protein therapeutics platform toward first-in-human clinical development. NORWALK, Conn., Aug. 10, 2026 /PRNewswire/ -- Lifespan Vision Ventures today announced that it is leading Remedium Bio, Inc.'s ("Remedium") $10 million Series A financing and has completed the round's initial …

We Said These 4 Dividend Aristocrats Could Soar. Here’s How They Did, Plus 3 New Picks.

Quick Read ABBV surged 47% and BDX gained 26% over the past year, both decisively beating the market as their overlooked dividend growth drove outsized returns. All four original picks kept raising dividends regardless of price, with PG marking its 70th consecutive year of …

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment. Continue Reading

Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock

Pfizer PFE stock has risen 6.9% since it announced second-quarter 2026 results on Aug. 4. Pfizer delivered a solid second quarter, beating estimates for both earnings and revenues. While earnings growth was flat year over year, revenues rose 1% on an operational basis. Strength …

Understanding Qiagen (QGEN) Reliance on International Revenue

Have you assessed how the international operations of Qiagen (QGEN) performed in the quarter ended June 2026? For this diagnostic products maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects. …

Zoetis (ZTS) Looked Like a Winner. What Went Wrong?

Brown Advisory, an investment management company, released its "Brown Advisory Global Leaders Strategy" for the second quarter of 2026 investor letter. A copy of the letter can be downloaded here. Brown Advisory's Global Leaders Strategy delivered a net return of 4.6% in the second …

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 31 July 2026

LUXEMBOURG, August 10, 2026--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): ANNEXE B Form to be used for the disclosure of the total number of voting rights and capital, in accordance with the law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of …

Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas

New State-of-the-Art Facility Will Create Nearly 500 Skilled Jobs and Accelerate the Delivery of Next-Generation Medicines Investment Furthers BMS' $40 Billion Commitment to American Innovation, Manufacturing and Economic Growth PRINCETON, N.J., August 10, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced the selection of Houston, …

Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?

Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J's MedTech ambitions, but the company is entering a market in which …

Beat the Market Like Zacks: Aveanna, FactSet, Shopify in Focus

Last Friday, the three major Wall Street indexes closed a winning week. The Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average gained 5.2%, 3.6% and 3%, respectively. Wall Street's strong weekly performance was driven by renewed investor optimism over the U.S. …

Interest Rates Could Still Rise in September: 5 High-Yield Passive Income Stocks Will Benefit

Quick Read With CPI hitting 3.8% and 30-year Treasury yields at their highest since 2007, a September 25-basis-point Fed rate hike looks virtually certain. Energy Transfer (ET) pays a 6.58% distribution yield while Prudential Financial (PRU) offers 4.64%, both positioned to profit as rates …

3 Beaten-Down Healthcare Stocks to Buy in August

Quick Read LLY grew Q1 revenue 56% and won FDA approval for the first oral GLP-1 pill, yet still trades 6% off its 52-week high. Healthcare has trailed SPY's 8% YTD gain, but JNJ's 64-year dividend streak and 20x forward P/E keep it compelling …

ACCESS Announces Multi-Year Strategic Agreement to Bring Advanced Cardiac Electrophysiology Technologies to Ambulatory Surgery Centers

Agreement supports ACCESS-affiliated ASCs in adopting the CARTO™ System and its integrated portfolio of mapping, intracardiac imaging, radiofrequency ablation and pulsed field ablation technologies NEW YORK, August 10, 2026--(BUSINESS WIRE)--ACCESS, through its physician-led group purchasing organization, ACCESS GPO, today announced a multi-year preferred portfolio …

Novo Nordisk Aktie: Bernstein senkt Prognosen und warnt vor deutlichem Abwärtspotenzial

ChemoMetec enters collaboration agreement with Roche Diagnostics

Chemometec A/S ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties' solutions in the field of bioprocess monitoring, ChemoMetec and Roche Diagnostics have today …

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru Inc. -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients – -- Phase 2b PLATEAU clinical trial interim analysis and results on track for calendar Q1 2027-- -- In June …

Update: Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date

(Updates with day of announcement in first paragraph, Novo Nordisk's affiliation in the second paragraph, and latest stock moves in the fourth paragraph.)Scholar Rock Holding (SRRK) said Friday that the FDA review of its apitegromab Biologics License Application for spinal Silver Upgrade to read …

Warum Viatris (VTRS) nach der Anhebung der Prognose und dem Abschluss eines Aktienrückkaufs im Wert von 1,15 Milliarden US-Dollar um 6,4 % nachgibt

US Stock Market Today: S&P 500 Futures Climb On Softer Jobs Data And Yields

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. The Morning Bull - US Market Morning Update Monday, Aug, 10 2026 US stock futures are pointing higher this morning, with the S&P …

Storebrand Europe Index - announcement of prospectus

Storebrand Asset Management AS Lysaker, 10 August 2026 Storebrand hereby announces the Prospectus with Articles of Association Appendix to the Prospectus ("tillæg" relevant to Danish investors) for Storebrand Europe Index, an index aware equity fund. The fund has been accepted for listing at Nasdaq …

BioNTech Aktie: 613 Millionen von Bristol Myers Squibb erwartet

Nvidia, Eli Lilly, and Disney Show It’s Time to Back the Top Dogs

Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now. Continue Reading